Compare Amplify Cybersecurity ETF (HACK) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Cybersecurity ETF vs Zimmer Biomet Holdings Inc — how do they compare? Amplify Cybersecurity ETF trades at $130.76 (market cap $3.50B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.8× Amplify Cybersecurity ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Amplify Cybersecurity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 28 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| HACK | ZBH | |
|---|---|---|
Market Cap | $3.50B | $16.95B |
Volume | 341,176 | 2,505,240 |
Sector | Sector/Thematic | Health |
52-Week High | $127.66 | $103.98 |
52-Week Low | $70.69 | $79.58 |
Typical Hold Time | 28 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HACK trades at $130.76, up 3.93% today and near its 52-week high, reflecting strong momentum amid bullish technical signals. The ETF benefits from rising cybersecurity demand driven by AI safety concerns and recent earnings beats from holdings like CrowdStrike. Technical indicators show a bullish trend with support at $124 and resistance at $126, while short interest has surged, indicating mixed sentiment.
Outlook remains positive due to sector tailwinds from AI-driven cyber threats, but risks include high valuation sensitivity and increased short interest. The ETF's diversified exposure to cybersecurity leaders offers growth potential, though investor caution is warranted given its proximity to record highs and competitive pressures.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
